echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Dermatol: Do we need to reconsider the diagnosis of melanoma in situ and severely dysplastic nevi?

    Br J Dermatol: Do we need to reconsider the diagnosis of melanoma in situ and severely dysplastic nevi?

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The reported incidence of cutaneous melanoma has risen sharply in many countries in recent decades, mainly due to increased diagnoses of melanoma in situ and small invasive melanoma
    .


    Incidence of invasive and metastatic melanoma and melanoma mortality remained relatively stable


    These strategies can also be applied to the diagnosis of severe dysplastic moles, so the diagnostic label and apparent equivalence to melanoma in situ (and associated treatment recommendations) in the MPATH-Dx reporting protocol may also lead to serious concerns for patients and clinicians anxiety
    .

    We searched and reviewed published evidence to support or reject changes in diagnostic thresholds and/or terminology used for these low-risk melanocytic lesions, and provided a detailed report on our findings
    .


    Three lines of evidence were assessed


    The second is evidence on the reliability of the diagnostic criteria for these two types of lesions
    .


    We found 14 replicate studies, 3 of which had a low risk of bias


    Third, there is evidence that diagnostic thresholds drift over time, so that even if the same melanocytic lesion was previously judged to be benign, a more "malignant" diagnostic label is now used
    .


    We found that two studies provided evidence for the diagnosis, both of which were at high risk of bias


    In conclusion, the sparse natural history evidence suggests that the risk of progression from melanoma in situ to invasive melanoma is uncertain but likely low, while the risk of progression from severe dysplastic nevi to invasive melanoma is negligible
    .


    These types of lesions may be better conceptualized as risk factors for aggressive melanoma rather than as prodromal symptoms


    Source: Semsarian CR, Ma T, Nickel B, Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? Br J Dermatol 2022 Jan 10; 

     

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.